Virtu Financial LLC Makes New Investment in Charles River Laboratories International, Inc. (NYSE:CRL)

Virtu Financial LLC acquired a new stake in Charles River Laboratories International, Inc. (NYSE:CRL) during the 3rd quarter, Holdings Channel.com reports. The firm acquired 3,051 shares of the medical research company’s stock, valued at approximately $601,000.

A number of other large investors have also made changes to their positions in CRL. Wealth Enhancement Advisory Services LLC boosted its stake in shares of Charles River Laboratories International by 33.5% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 6,114 shares of the medical research company’s stock worth $1,263,000 after purchasing an additional 1,535 shares during the last quarter. Envestnet Portfolio Solutions Inc. boosted its position in Charles River Laboratories International by 0.8% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 9,706 shares of the medical research company’s stock worth $2,005,000 after acquiring an additional 75 shares during the last quarter. Blue Trust Inc. grew its stake in Charles River Laboratories International by 19.1% in the 2nd quarter. Blue Trust Inc. now owns 1,459 shares of the medical research company’s stock worth $301,000 after acquiring an additional 234 shares during the period. Nisa Investment Advisors LLC raised its holdings in Charles River Laboratories International by 13.8% in the 2nd quarter. Nisa Investment Advisors LLC now owns 11,202 shares of the medical research company’s stock valued at $2,314,000 after acquiring an additional 1,361 shares during the last quarter. Finally, Pallas Capital Advisors LLC lifted its stake in shares of Charles River Laboratories International by 5.9% during the 2nd quarter. Pallas Capital Advisors LLC now owns 11,585 shares of the medical research company’s stock worth $2,532,000 after purchasing an additional 647 shares during the period. Institutional investors and hedge funds own 98.91% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on CRL shares. Citigroup lowered Charles River Laboratories International from a “neutral” rating to a “sell” rating and dropped their target price for the company from $215.00 to $175.00 in a research note on Tuesday, October 1st. Redburn Atlantic started coverage on shares of Charles River Laboratories International in a research note on Monday, October 14th. They set a “sell” rating and a $151.00 price objective for the company. Evercore ISI raised their target price on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a research report on Thursday, November 7th. CLSA lowered shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price target for the company. in a research report on Monday, November 18th. Finally, Bank of America decreased their price target on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a report on Friday. Three equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $214.00.

Charles River Laboratories International Stock Performance

NYSE:CRL opened at $190.46 on Friday. The firm’s fifty day simple moving average is $194.35 and its 200 day simple moving average is $203.02. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61. Charles River Laboratories International, Inc. has a twelve month low of $176.48 and a twelve month high of $275.00. The firm has a market capitalization of $9.74 billion, a price-to-earnings ratio of 23.84, a PEG ratio of 5.00 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $975.99 million. During the same period last year, the company posted $2.72 earnings per share. The firm’s revenue was down 1.6% compared to the same quarter last year. As a group, equities research analysts expect that Charles River Laboratories International, Inc. will post 10.18 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the sale, the director now owns 12,386 shares of the company’s stock, valued at $2,676,862.32. This trade represents a 34.83 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.30% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).